Last reviewed · How we verify
Stronger Neo-Minophagen C
Stronger Neo-Minophagen C is a Small molecule drug developed by Chimei Medical Center. It is currently FDA-approved.
At a glance
| Generic name | Stronger Neo-Minophagen C |
|---|---|
| Sponsor | Chimei Medical Center |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- SNMC (Stronger Neo-Minophagen C ) for Acute Hepatitis Post Transarterial Chemoembolization Therapy (PHASE4)
- Efficacy of Peginterferon Alfa-2b (SCH 054031) vs Glycyrrhizin in Interferon (IFN)-Treated Patients With Chronic Hepatitis C and F2/F3 Liver Fibrosis (P04773) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Stronger Neo-Minophagen C CI brief — competitive landscape report
- Stronger Neo-Minophagen C updates RSS · CI watch RSS
- Chimei Medical Center portfolio CI
Frequently asked questions about Stronger Neo-Minophagen C
What is Stronger Neo-Minophagen C?
Stronger Neo-Minophagen C is a Small molecule drug developed by Chimei Medical Center.
Who makes Stronger Neo-Minophagen C?
Stronger Neo-Minophagen C is developed and marketed by Chimei Medical Center (see full Chimei Medical Center pipeline at /company/chimei-medical-center).
What development phase is Stronger Neo-Minophagen C in?
Stronger Neo-Minophagen C is FDA-approved (marketed).
Related
- Manufacturer: Chimei Medical Center — full pipeline
- Compare: Stronger Neo-Minophagen C vs similar drugs
- Pricing: Stronger Neo-Minophagen C cost, discount & access